1-4 of 4
Philip Lecane
Close
Sort by
Journal Articles

Motexafin Gadolinium Causes Apoptosis in Lymphoma Cells by Increasing Intracellular Free Zinc and Disrupting Redox Balance.

Darren Magda, PhD, Philip Lecane, PhD, Mazen W. Karaman, PhD, Mint Sirisawad, PhD, Louie Naumovski, MD, PhD, Richard A. Miller, MD, Joseph G. Hacia, PhD
Journal: Blood
Blood (2005) 106 (11): 4827.
https://doi.org/10.1182/blood.V106.11.4827.4827
Published: 2005
Journal Articles

Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells

Andrew M. Evens, Philip Lecane, Darren Magda, Sheila Prachand, Seema Singhal, Jeff Nelson, Richard A. Miller, Ronald B. Gartenhaus, Leo I. Gordon
Journal: Blood
Blood (2005) 105 (3): 1265–1273.
https://doi.org/10.1182/blood-2004-03-0964
Published: 2005
Journal Articles

Sapphyrins Exhibit Tumor Selectivity and Efficacy in Animal Models of Hematologic Malignancies.

Louie Naumovski, MD-PhD, Mint Sirisawad, BA, Philip Lecane, PhD, Jason Ramos, PhD, Darren Magda, PhD, Zhong Wang, PhD, Patti Thiemann, BS, Garry Boswell, PharmD, Dong-Gyu Cho, BS, Jonathan Sessler, PhD, Richard A. Miller, MD
Journal: Blood
Blood (2004) 104 (11): 2501.
https://doi.org/10.1182/blood.V104.11.2501.2501
Published: 2004
Journal Articles

Motexafin Gadolinium Mobilizes Zinc and Inhibits Thioredoxin Reductase in Human Lymphoma Cell Lines.

Darren Magda, Ph.D., Philip Lecane, Ph.D., Lepp Cheryl, M.S., Richard A. Miller, M.D.
Journal: Blood
Blood (2004) 104 (11): 4316.
https://doi.org/10.1182/blood.V104.11.4316.4316
Published: 2004